The challenges of drug provision in cancer genome medicine

Abstract

　In June 2019, the Japanese government reimbursed comprehensive genomic profiling（CGP）tests. While CGP tests have been incorporated into routine clinical.　The Challenges of Drug Provision in Cancer Genome Medicine practice, CGP tests are only available at designated hospitals. Moreover, the indication is restricted to patients with disease progression during standard therapies or without standard treatments. According to the data reported by the Ministry of Health, Labour and Welfare, the proportion of receiving genomically-matched therapies was 8.1% and the accessibility of matched therapies is a big issue in current precision oncology in Japan. To improve the drug accessibility, a prospective trial of patient-proposed healthcare services with multiple targeted agent（BELIEVE trial）is on-going at 12 designated core hospitals for genomic medicine.